Cargando…

Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab

Detalles Bibliográficos
Autores principales:	Kowarik, Markus C., Hoshi, Muna, Hemmer, Bernhard, Berthele, Achim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751152/ https://www.ncbi.nlm.nih.gov/pubmed/26913290 http://dx.doi.org/10.1212/NXI.0000000000000208

Ejemplares similares

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Adverse Events in NMOSD Therapy
por: Giglhuber, Katrin, et al.
Publicado: (2022)

Paroxysmal sneezing in NMOSD: Further evidence of the localization of the human sneeze center
por: López-Chiriboga, A. Sebastian, et al.
Publicado: (2016)

Contribution of blood vessels to retinal nerve fiber layer thickness in NMOSD
por: Oertel, Frederike C., et al.
Publicado: (2017)

Case of alemtuzumab-related alopecia areata management in MS
por: Chan, Jillian K., et al.
Publicado: (2018)

Alemtuzumab and intrathecal methotrexate failed in the therapy of Rasmussen encephalitis
por: Liba, Zuzana, et al.
Publicado: (2017)

Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms in NMOSD
por: Mizuno, Yuri, et al.
Publicado: (2018)

Paraneoplastic NMOSD associated with EG junction adenocarcinoma expressing unprotected AQP4
por: Sudo, Atsushi, et al.
Publicado: (2018)

Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions
por: Ventura, Rachel E., et al.
Publicado: (2016)

Spontaneous remission lasting more than a decade in untreated AQP4 antibody–positive NMOSD
por: Pandit, Lekha, et al.
Publicado: (2017)

Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis
por: Brannigan, Jamie, et al.
Publicado: (2020)

Refractory chronic spontaneous urticaria after the use of alemtuzumab in multiple sclerosis
por: Hu, Hannah, et al.
Publicado: (2020)

Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy
por: Rinaldi, Francesca, et al.
Publicado: (2017)

Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion
por: Tzartos, John S., et al.
Publicado: (2020)

Anti–GABA-A Receptor Antibody-Mediated Epilepsia Partialis Continua After Treatment With Alemtuzumab: A Case Report
por: Ratuszny, Dominica, et al.
Publicado: (2023)

Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients
por: van der Zwan, Marieke, et al.
Publicado: (2020)

Rituximab during pregnancy in neuromyelitis optica: A case report
por: Miranda-Acuña, Jahir, et al.
Publicado: (2019)

Disease exacerbation after rituximab induction in neuromyelitis optica
por: Perumal, Jai S., et al.
Publicado: (2015)

Effective treatment of CLIPPERS with long-term use of rituximab
por: Cipriani, Veronica P., et al.
Publicado: (2018)

Plasmapheresis for NMOSD: Not a Rescue Therapy Anymore!?
por: Bhatia, Rohit, et al.
Publicado: (2019)

Repeated treatments with rituximab in a patient with amyloid-like IgM deposition neuropathy
por: Kadoya, Masato, et al.
Publicado: (2016)

Opsoclonus-Myoclonus Syndrome during Rituximab Treatment for Autoimmune Autonomic Ganglionopathy
por: Dumitrascu, Oana M., et al.
Publicado: (2017)

CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1
por: Wasling, Pontus, et al.
Publicado: (2019)

CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation
por: Kowarik, Markus C, et al.
Publicado: (2012)

Refractory IgG4-related intracranial hypertrophic pachymeningitis responded to rituximab
por: Liao, Bing, et al.
Publicado: (2014)

Rituximab for Sjögren syndrome–associated type II mixed cryoglobulinemic cerebral vasculitis
por: Lioger, Bertrand, et al.
Publicado: (2016)

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
por: Rakocevic, Goran, et al.
Publicado: (2018)

Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases
por: Lepennetier, Gildas, et al.
Publicado: (2019)

Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient
por: Massey, Thomas H., et al.
Publicado: (2017)

The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies
por: Briani, Chiara, et al.
Publicado: (2022)

Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case Report
por: Wicklein, Rebecca, et al.
Publicado: (2021)

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab
por: Pawlitzki, Marc, et al.
Publicado: (2018)

Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
por: Esmaeili, Sara, et al.
Publicado: (2021)

Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD
por: Derdelinckx, Judith, et al.
Publicado: (2021)

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions
por: Kleiter, Ingo, et al.
Publicado: (2018)

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension
por: Pittock, Sean J, et al.
Publicado: (2021)

Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD
por: Das, Gitanjali, et al.
Publicado: (2018)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Prognostic value of white matter lesion shrinking in early multiple sclerosis: An intuitive or naïve notion?
por: Pongratz, Viola, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n3egdf18dcj6lj7f189g6hl3tp